These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 31844014)

  • 21. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for multidrug-resistant Gram-negatives in urinary tract infections.
    Zollner-Schwetz I; König E
    Curr Opin Urol; 2023 May; 33(3):173-179. PubMed ID: 36861769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
    Doi Y
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S565-S575. PubMed ID: 31724043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
    Chahine EB; Sourial M; Ortiz R
    Consult Pharm; 2015 Dec; 30(12):695-705. PubMed ID: 26671269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
    De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
    Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
    Chiotos K; Hayes M; Gerber JS; Tamma PD
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.
    Tompkins K; van Duin D
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2053-2068. PubMed ID: 34169446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
    O'Donnell JN; Lodise TP
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0025622. PubMed ID: 35727059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.
    Buckman SA; Krekel T; Muller AE; Mazuski JE
    Expert Opin Pharmacother; 2016 Dec; 17(17):2341-2349. PubMed ID: 27758148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
    Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of novel β-lactams and β-lactam/β-lactamase inhibitor combinations with implications for pediatric use.
    Olney KB; Thomas JK; Johnson WM
    Pharmacotherapy; 2023 Jul; 43(7):713-731. PubMed ID: 36825478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antimicrobial treatment options for severe Gram-negative infections.
    Hetzler L; Kollef MH; Yuenger V; Micek ST; Betthauser KD
    Curr Opin Crit Care; 2022 Oct; 28(5):522-533. PubMed ID: 35942725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.